Imperial College London
Portrait Picture

Dr David C Muller

Faculty of Medicine, School of Public Health

Senior Lecturer in Cancer Epidemiology and Biostatistics
 
 
 
//

Contact

 

david.muller

 
 
//

Location

 

School of Public HealthWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sasamoto:2019:10.1186/s13048-019-0591-4,
author = {Sasamoto, N and Babic, A and Rosner, BA and Fortner, RT and Vitonis, AF and Yamamoto, H and Fichorova, RN and Titus, LJ and Tjonneland, A and Hansen, L and Kvaskoff, M and Fournier, A and Mancini, FR and Boeing, H and Trichopoulou, A and Peppa, E and Karakatsani, A and Palli, D and Grioni, S and Mattiello, A and Tumino, R and Fiano, V and Onland-Moret, NC and Weiderpass, E and Gram, IT and Quiros, JR and Lujan-Barroso, L and Sanchez, M-J and Colorado-Yohar, S and Barricarte, A and Amiano, P and Idahl, A and Lundin, E and Sartor, H and Khaw, K-T and Key, TJ and Muller, D and Riboli, E and Gunter, M and Dossus, L and Trabert, B and Wentzensen, N and Kaaks, R and Cramer, DW and Tworoger, SS and Terry, KL},
doi = {10.1186/s13048-019-0591-4},
journal = {Journal of Ovarian Research},
pages = {1--12},
title = {Development and validation of circulating CA125 prediction models in postmenopausal women},
url = {http://dx.doi.org/10.1186/s13048-019-0591-4},
volume = {12},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundCancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between individuals. Personal characteristics that influence CA125 could be used to improve its performance as screening biomarker.MethodsWe developed and validated linear and dichotomous (≥35 U/mL) circulating CA125 prediction models in postmenopausal women without ovarian cancer who participated in one of five large population-based studies: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 26,981), European Prospective Investigation into Cancer and Nutrition (EPIC, n = 861), the Nurses’ Health Studies (NHS/NHSII, n = 81), and the New England Case Control Study (NEC, n = 923). The prediction models were developed using stepwise regression in PLCO and validated in EPIC, NHS/NHSII and NEC.ResultThe linear CA125 prediction model, which included age, race, body mass index (BMI), smoking status and duration, parity, hysterectomy, age at menopause, and duration of hormone therapy (HT), explained 5% of the total variance of CA125. The correlation between measured and predicted CA125 was comparable in PLCO testing dataset (r = 0.18) and external validation datasets (r = 0.14). The dichotomous CA125 prediction model included age, race, BMI, smoking status and duration, hysterectomy, time since menopause, and duration of HT with AUC of 0.64 in PLCO and 0.80 in validation dataset.ConclusionsThe linear prediction model explained a small portion of the total variability of CA125, suggesting the need to identify novel predictors of CA125. The dichotomous prediction model showed moderate discriminatory performance which validated well in independent dataset. Our dichotomous model could be valuable in identifying healthy women who may have elevated CA125 lev
AU  - Sasamoto,N
AU  - Babic,A
AU  - Rosner,BA
AU  - Fortner,RT
AU  - Vitonis,AF
AU  - Yamamoto,H
AU  - Fichorova,RN
AU  - Titus,LJ
AU  - Tjonneland,A
AU  - Hansen,L
AU  - Kvaskoff,M
AU  - Fournier,A
AU  - Mancini,FR
AU  - Boeing,H
AU  - Trichopoulou,A
AU  - Peppa,E
AU  - Karakatsani,A
AU  - Palli,D
AU  - Grioni,S
AU  - Mattiello,A
AU  - Tumino,R
AU  - Fiano,V
AU  - Onland-Moret,NC
AU  - Weiderpass,E
AU  - Gram,IT
AU  - Quiros,JR
AU  - Lujan-Barroso,L
AU  - Sanchez,M-J
AU  - Colorado-Yohar,S
AU  - Barricarte,A
AU  - Amiano,P
AU  - Idahl,A
AU  - Lundin,E
AU  - Sartor,H
AU  - Khaw,K-T
AU  - Key,TJ
AU  - Muller,D
AU  - Riboli,E
AU  - Gunter,M
AU  - Dossus,L
AU  - Trabert,B
AU  - Wentzensen,N
AU  - Kaaks,R
AU  - Cramer,DW
AU  - Tworoger,SS
AU  - Terry,KL
DO  - 10.1186/s13048-019-0591-4
EP  - 12
PY  - 2019///
SN  - 1757-2215
SP  - 1
TI  - Development and validation of circulating CA125 prediction models in postmenopausal women
T2  - Journal of Ovarian Research
UR  - http://dx.doi.org/10.1186/s13048-019-0591-4
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000499463700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-019-0591-4
UR  - http://hdl.handle.net/10044/1/80630
VL  - 12
ER  -
Download